Nicholas Cortellucci

Atrium Research

Recent Articles about Cannara Biotech Inc.

Record Profits, a Vape Market Landgrab, and a CA$250M Facility Bought for CA$27M 03/05/2026

Atrium Research initiated coverage on Cannara Biotech Inc. (LOVE:TSX; LOVFF:OTCQX; BCB0:FSE), citing the company's dominant position in Quebec's new vape category, best-in-class EBITDA margins of 29%, and a capital-efficient expansion path at its Valleyfield facility that could unlock 100,000 kg of annual production capacity by FY30.